NCT02952469 is a EARLY_PHASE1 clinical trial of (68Ga)PSMA-HBED-CC in Prostatic Neoplasms, sponsored by University of Iowa.

Who is sponsoring NCT02952469?

NCT02952469 is sponsored by University of Iowa.

What drugs are being tested in NCT02952469?

Interventions in NCT02952469: (68Ga)PSMA-HBED-CC.

What condition does NCT02952469 study?

NCT02952469 studies Prostatic Neoplasms.

Is NCT02952469 still recruiting?

NCT02952469 is currently completed. Last updated 3 September 2024.

Last reviewed 2024-09-03 · How we verify

NCT02952469

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC

Completed EARLY_PHASE1 Last updated 3 September 2024

What this trial tests

EARLY_PHASE1 trial testing (68Ga)PSMA-HBED-CC in Prostatic Neoplasms in 22 participants. Completed in 25 April 2022.

Timeline

14 July 2016

Primary endpoint
25 April 2022

25 April 2022

Quick facts

Lead sponsor	University of Iowa
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	22
Start date	14 July 2016
Primary completion	25 April 2022
Estimated completion	25 April 2022
Sites	1 location across United States

Drugs / interventions tested

(68Ga)PSMA-HBED-CC

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →

Sponsor

University of Iowa

Who can join

18 and older, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this Radioactive Drug Research Committee (RDRC) study is to collect initial data regarding biodistribution, reproducibility, and dosimetry for the radiotracer Ga-68 PSMA-HBED-CC, an agent which may be useful for the early detection of metastatic prostate cancer. Investigators will use a test and re-test design in all patients to determine reproducibility of lesion detection and signal intensity, and will include dynamic imaging in some patients for the purposes of dosimetry. Patients with known metastatic prostate cancer will be recruited and imaged on two occasions within the course of 15 days.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Repeatability of <sup>68</sup>Ga-PSMA-HBED-CC PET/CT-Derived Total Molecular Tumor Volume.
Seifert R, Sandach P, Kersting D, Fendler WP, et al · · 2022 · cited 17× · PMID 34446454 · DOI 10.2967/jnumed.121.262528

Verify or expand the search:

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other University of Iowa trials

Trials by the same sponsor.

NCT07224269 — Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis · EARLY_PHASE1 · not yet recruiting
NCT07244809 — Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adve · NA · recruiting
NCT07097961 — Paediatric Post-TB Pulmonary Rehab Study · NA · recruiting
NCT06951594 — Robotic-Assisted Versus Manual Electrode Array Insertion · NA · recruiting
NCT06710119 — Effect of Custom Dynamic Orthoses on Forefoot Loading · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02952469 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Iowa
Last refreshed: 3 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02952469.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing